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ABSTRACT
Differential Expressions of Cell Cycle Regulatory Proteins and ERK 1/2
Characterize the Proliferative Smooth Muscle Cell Phenotype Induced by
Allylamine.  (August 2003)
Sarah Anne Louise Jones, B.S., Dalhousie University, Canada;
D.V.M., Atlantic Veterinary College, University of Prince Edward Island, Canada
Co-Chairs of Advisory Committee: Dr. Emily Wilson
                                                                   Dr. Kenneth S. Ramos
Chronic oxidative injury by allylamine induces proliferative vascular smooth
muscle cell (vSMC) phenotypes in the rat aorta similar to those seen in rodent and
human atherosclerotic lesions.  In this study, we evaluate the potential role of cyclin
dependent kinase inhibitors, p21 and p27, and extracellular regulated kinases
(ERK1/2) to mediate the proliferative advantage of oxidatively stressed (i.e.
allylamine injured) vSMC. Isolated rat aortic SMC from allylamine treated and
control rats were cultured on different extracellular matrix (ECM) proteins.
Following mitogen restriction, cultures were stimulated with serum with or without
inhibitors of NF-κB or MEK.  Western blot analysis was performed to identify
protein differences between treatment groups.  Basal levels of p21 were 1.6 fold
higher in randomly cycling allylamine cells than control counterparts seeded on a
plastic substrate, a difference lost when cells were seeded on collagen. p27 levels
were comparable in both cell types irrespective of substrate. Basal levels of p21 and
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p27 were 1.4 fold higher in G0 synchronized allylamine cells compared with G0
synchronized control cells seeded on a plastic substrate.  Following cell cycle
progression, differences in protein levels were not detected.  Treatment with 100 nM
pyrollidine dithiocarbamate (PDTC) resulted in significant decreases in p21 and p27
in allylamine cells versus control cells following serum stimulation for 9 hours. This
decrease was even greater for p21 in allylamine cells when grown on collagen
relative to control cells. Alterations in peak and temporal activation of ERK1/2 were
observed in allylamine cells seeded on a plastic substrate as compared to control
cells, following serum stimulation.  Seeding on collagen decreased the enhanced
peak phosphorylation of ERK1/2 and increased the sustained activity in allylamine
cells compared with control counterparts.  Inhibition of ERK1/2 activity resulted in
reduced p21 expression in both cells types, but the response was markedly enhanced
in allylamine cells, and preferentially observed on a restrictive collagen substrate.
We conclude that induction of proliferative (i.e. atherogenic) phenotypes following
repeated cycles of oxidative injury involves ERK1/2 activity and modulation of the
cyclin dependent kinase inhibitors, p21 and p27, in a matrix-dependent manner.
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1CHAPTER I
INTRODUCTION
1.1. Atherosclerosis
Atherosclerosis or “ hardening of the arteries” is a systemic disease involving
all of the major arteries supplying the heart, brain, kidneys and extremities.  In the
United States and most other Western countries, atherosclerosis is a leading cause of
illness and death with carotid and coronary artery involvement resulting in strokes
and heart attacks, respectively [1].  Atherosclerosis is a disease of the arterial intima
resulting in the formation of atheromatous plaques followed by stenosis and
occlusion of the vessel lumen. Development of atherosclerosis involves multiple
changes in the vascular wall, including damage to endothelial cells and vascular
smooth muscle cells (vSMC), influx of inflammatory cells to the damaged site,
release of inflammatory mediators within the vessel wall, proliferation of vSMC in
response to mediators, and accumulation of lipids and matrix proteins. While the
contributing cell types and characteristics of the plaque are well characterized,
molecular mechanisms responsible for the initiation and propagation of these
pathologies remain elusive. Much of the early research in atherogenesis revolved
around the cholesterol theory, or hypercholesterolemia, as the major risk factor in the
development   of   atherosclerosis   [2,3].      Elevated    serum   cholesterol,   due   to
The journal used as a model for this dissertation is Cardiovascular Research.
2consumption of diets rich in lipids or due to a hereditary defect of lipid metabolism,
results in intracellular accumulation of lipids and formation of atherosclerotic
plaques.  Experimentally, increasing plasma cholesterol levels through dietary
manipulation or utilizing naturally defective or genetically modified animals with
alterations in lipoprotein metabolism have been reliable methods for induction of
atherogenesis [2].  More recently, however, evidence for involvement of numerous
factors, other than hypercholesterolemia, has been revealed [3,4]. It is now believed
that there are multiple factors contributing to atherogenesis including serum
cholesterol levels, hypertension, aging, obesity, oxidative stress, inflammation,
cigarette smoking and other emerging risk factors.
Beyond cholesterol, there have been two major theories of atherogenesis,
both originally proposed in the early ‘70s.  The response-to-injury hypothesis
involves injury to the endothelial cells lining the vessel lumen [5].  The endothelium
is complex and dynamic responding to environmental stimuli and activating
vasoactive substances that mediate vascular tone, structure and function, and
influence vSMC growth and differentiation [6].  It is known that de-differentiation of
vSMC from native contractile phenotypes to highly proliferative and synthetic
phenotypes is a key step in atherogenesis.  The release of growth factors and
cytokines from injured endothelial cells and migrating inflammatory cells, such as
monocytes and lymphocytes, promotes the proliferation of vSMC and alteration of
extracellular matrix protein secretion [7].
3The second hypothesis introduces atherosclerosis as a carcinogenic process
whereby the atherosclerotic plaque is a benign neoplasm of the vessel wall stemming
from the monoclonal expansion of a single mutated vSMC [8]. In this case, genetic
reprogramming of vSMC is a hallmark of atherogenesis following injury or toxic
insult.  It is difficult to separate these hypotheses, as most likely it is a combination
of events that ultimately leads to atherosclerosis.  It is expected that if endothelial
injury resulted in aberrant vSMC proliferation, following repair of the injury or
removal of the injurious insult, the vessel wall would return to normal. However, this
does not occur spontaneously supporting the progression of atherosclerosis as
genetic reprogramming within the vSMC.  As well, altered vSMC proliferation can
occur in vitro in the absence of endothelial cells, macrophages and other non-cellular
factors, implying that endothelial injury alone is unlikely to be the sole factor in
atherogenesis.  Aberrant vSMC proliferation, however, appears to be a consistent
abnormality in atherogenesis.
1.2. Vascular Smooth Muscle Cell Growth and Differentiation
VSMC exist in a diverse range of phenotypes.  In normal mature blood
vessels, vSMC function to regulate vessel diameter and blood flow.  In order to
provide this function, the differentiated, or contractile, phenotype of vSMC is
predominant. During vascular remodeling, vSMC alter their phenotype to a non-
contractile or synthetic state resulting in generation of intimal vascular lesions [9].
These de-differentiated, or synthetic, vSMC have reduced expression of proteins
4required for muscle cell contraction and have increased synthesis of extracellular
matrix proteins.  Extracellular matrix proteins such as fibronectin and laminin are
known to help control the growth and phenotype of vSMC, with differential effects
observed on these growth matrices [10].  Cell adhesion to fibronectin supports cell
proliferation and the activation of focal adhesion kinase (FAK), while cell adhesion
to laminin does not. Also, cell growth on fibronectin results in proliferation and low
expression levels of smooth muscle myosin, whereas growth on laminin slows
proliferation and increases expression levels of smooth muscle myosin.  These
findings indicate that integrin signaling pathways have a profound effect on vSMC
proliferation and phenotype.
Several factors contribute to phenotype, growth, proliferation and migration
of vSMC [11,12].  Those to be discussed in detail include integrin- and growth
factor- mediated signaling and the coordinated effort of both signaling pathways.
1.3. Integrins and Integrin Mediated Signaling
Integrins are a large family of heterodimeric transmembrane receptors that
link the extracellular matrix to the cytoskeleton.  Integrin function is to integrate the
5extracellular matrix to the interior cytoskeleton of the cell, hence the name.  Integrins
consist of noncovalently bound α- and β-subunits.  To date, there exist 24 receptors,
which are the result of heterodimeric combinations of α- and β-subunits.  Currently,
18 α- and 8 β-subunits have been identified [13].  Each of the α- and β-subunits
contains a large extracellular domain, a single membrane spanning region and a short
cytoplasmic domain (Figure 1) [14].  The extracellular domains of the α and β
subunits are non-covalently linked to form a globular head domain that binds
specific components of the extracellular matrix with ligand specificity determined by
a particular combination of α- and β- subunits [15].  Cytoplasmic domains of
integrin subunits, particularly α-subunits, display highly divergent sequences
allowing each αβ heterodimeric combination to have its own signaling properties
[16,17].  For example, αvβ3 integrin interacts with a variety of extracellular matrix
ligands, including vitronectin, fibronectin, and osteopontin (OPN); while α5β1 shows
ligand specificity exclusively for fibronectin; and α1β1 has predominant ligand
specificity for collagen [18].
6Figure 1:  Subunit structures of a representative mammalian integrin receptor
(fibronectin receptor).  Following extracellular matrix recognition, the α and β
subunits noncovalently bind forming a globular head structure.  Within the cytosol,
at the C-terminus of the protein, binding sites exist for cytoskeletal and cytoplasmic
proteins.  Once bound to cytoplasmic structures, further protein recruitment and
phosphorylation cascades occur resulting in intracellular transmission of signals from
the external cellular environment (ECM – extracellular matrix).
Following cellular adhesion and clustering, integrins recruit cytoskeletal and
cytoplasmic proteins, allowing anchorage of the newly formed complexes to the
7actin cytoskeleton.  Local remodeling of the actin cytoskeleton leads to formation of
focal adhesions.  Focal adhesions not only supply a structural link between the
extracellular matrix and the cytoskeleton, they are also important sites of signal
transduction.  Integrins, as a class of signaling receptors, do not share the typical
kinase or phosphatase domains or G protein association that other signaling receptors
have [19-21].  However, signal transduction properties of integrins are well
established.  It has been proposed that integrin signaling may occur through signal
transmission during cytoskeletal reorganization, or it may in fact occur through
protein phosphorylation cascades similar to other signaling receptors.  Recent
evidence points to the presence and contribution of both pathways, either alone or in
combination, during integrin signal transduction [22,23].
There are many transmembrane proteins, including growth factor receptors,
that interact with integrins [14,24].  The interaction of integrins with growth factor
receptors may aid in recruitment of receptor clustering, may delay internalization of
the receptor following ligand binding, or may prevent dephosphorylation thereby
sustaining or augmenting receptor signaling efficiency [25].   It is clear that cell
survival and proliferation require interaction and adhesion with the extracellular
matrix.  Neoplastic cells are altered to such an extent that they no longer require
anchorage to the extracellular matrix for cell survival [13,15,26].  It is the
coordinated efforts of integrin- and growth factor- mediated signaling that modulate
cell cycle progression and thus cell growth and differentiation [15,27,28].
8There are also many cytoplasmic proteins that associate with the cytoplasmic
domains of integrins and with the focal adhesion complex.  Many of these proteins
are involved in downstream signaling cascades important in cell cycle progression,
including Shc, Grb 2 and several protein kinases [14,29]. Of considerable importance
is the presence of a specific tyrosine kinase known as pp125 focal adhesion kinase
(FAK) that is localized to focal adhesions [30,31]. FAK becomes phosphorylated and
activated when ligands bind to integrin receptors.  Phosphorylated FAK then binds
and activates downstream signaling cascades including Src, Grb2, and PI3-kinase. In
addition to FAK, several other protein kinases participate in integrin-mediated
signaling, including protein kinase C (PKC) and extracellular regulated kinases
(ERK(s)) [32,33].  It is interesting to note that activation of ERK through integrin
signaling is independent of ras which reveals an alternate ERK activation pathway
from tyrosine kinase receptor activation following growth factor binding [34].
1.4. Extracellular Regulated Kinases (ERKs)
Intricately involved in regulation of vSMC phenotype is the activation of
ERKs [35].  Alterations in intracellular signaling cascades following ERK activation
are known to play a vital role in cell growth, differentiation and proliferation through
modulation of gene expression.  ERKs are known to be activated by growth factor
binding to tyrosine kinase receptors as well as ligand binding to integrins
[15,22,26,35].  The phenotype of vSMC is also largely dependent on the interaction
of the cell with extracellular matrix proteins and extracellular environment.
9Attachment of vSMC to fibronectin, an arginine-glycine-aspartate (RGD) sequence
containing protein, promotes conversion of contractile vSMC to proliferative
phenotypes [36].  As in most other cell types, modulation of vSMC growth and
proliferation is highly dependent on ERK signaling [24].  Zhu and colleagues have
demonstrated that the kinetics of ERK activation by growth factors differ from those
observed following integrin signal transduction [37], perhaps indicating that discrete
differences exist in intracellular signaling mediators and in nuclear translocation of
activated ERKs.
Figure 2 outlines the proteins involved in activation of ERKs resulting in
nuclear translocation where interaction with a number of transcription factors
modulating gene expression occurs.  Ligand binding to the growth factor receptor
results in tyrosine kinase receptor dimerization and autophosphorylation.  This
phosphorylation event causes the activation of several intracellular signaling
cascades including diacylglycerol (DAG), inositoltriphosphate (IP3), PKC and the
ras/raf/MAP kinase kinase (MEK) pathway leading to ERK activation.
Recent evidence has shown that not only is ERK activation pivotal to cell
growth and differentiation, but prolonged ERK activation via integrin signaling (in
the absence of mitogen stimulation) is associated with phenotypic modulation of
vSMC when grown on fibronectin [11].  This prolonged ERK activation is also
associated with increased nuclear translocation of activated ERK.  As well, it has
been shown that prolonged ERK activation alters cell cycle progression through
modulation of cyclin D1 activity in late G1 phase of the cell cycle [38-41].
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Figure 2: Activation of intracellular signaling cascades through
integrin/extracellular matrix and growth factor receptor signaling.  Growth factor
binding to its receptor causes receptor dimerization and autophosphorylation, which
activates a variety of signaling pathways including IP3, DAG, PKC and activation of
ras.  Ligand binding to integrin receptors results in phosphorylation of FAK and the
association of FAK with src. These phosphorylated complexes provide sites of
attachment for Grb-2/SOS, a complex that initiates nucleotide exchange of inactive
ras-GDP to active ras-GTP.  Ras-GTP activates raf to begin a phosphorylation
cascade involving MAP kinase kinases (MEKs) and ERKs.  Once activated, ERKs
translocate to the nucleus to activate various transcription factors (TF) modifying
gene expression.
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1.5. Cell Cycle Regulation
Modulation of cell cycle proteins is the final common pathway of cell
mitosis, growth arrest, or apoptosis.    There are several checkpoints in the cell cycle
that allow a cell to pass through a quiescent state to mitosis and division (Figure 3).
Within the G1 phase of cell growth, the cell is preparing for DNA synthesis, a
necessary step for cell division.  Cyclins D and E and the cdk inhibitors p27 and  p21
Figure 3: Phases of the cell cycle.   Schematic representation of the cell cycle
with notation of key regulatory proteins and the phase(s) in which they exercise their
regulation.
are important components of the cellular machinery necessary for cells to proceed
through G1 to S phase. Alterations in the expression of cell cycle proteins are also
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elicited by both growth factors and adhesion to the extracellular matrix [41-45].
Elevations in cyclin D1 levels are dependent on prolonged ERK1/2 activation in
adhered cells [41]. Following cyclin/cdk complex formation, the phosphorylation
status of key proteins, including the retinoblastoma protein (Rb), becomes altered
allowing the cell to pass into S phase.
Integrins and growth factor receptors cooperate at several levels to ensure the
proper control of cell proliferation.  Both growth factor receptor binding and cell
adhesion are required for transmitting signals to the ras/raf/MEK/ERK signaling
pathway.  Activation and nuclear translocation of ERKs result in an increased cyclin
D1 transcription, and requires both growth factor- and integrin-mediated signal
transduction. Cyclin D1 expression induces the activation of cdk4/6 kinases.
Typically, the presence of the cdk inhibitors, p27and p21, inhibit cyclin D1/cdk4/6
complex formation thereby inhibiting progression of the cell through G1 [13].
Integrin receptor activation functions to stimulate a degradation pathway that
specifically degrades the negative cell cycle regulators p27 and p21, allowing the
activation of cyclin  E-cdk2  complexes.   Activation of both cdk4/6- and cdk2-cyclin
complexes are required for hyperphosphorylation of the retinoblastoma protein (Rb),
causing the release of the transcription factor,  E2F,  which is required  for  increased
transcription of cyclin A.  Cyclin A-cdk2 complexes are required for entry into S
phase (Figure 4) [13].  Through this coordinated effort of integrin- and growth
factor-mediated signaling, a cell may progress through G1 to S phase.
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Figure 4:  ERK regulation of cell cycle proteins following integrin/extracellular
matrix and/or growth factor receptor activation.  Cyclin D1 levels increase following
nuclear translocation of activated ERKs.  Complex formation between cyclin D1 and
cdk4/6 results in phosphorylation of the retinoblastoma protein (Rb) which results in
release of the transcription factor E2F.  Binding of E2F to its DNA binding site
results in increased transcription of cyclin A, which ultimately allows progression to
S phase.  Integrin activation also results in degradation of p27/p21 proteins that are
bound to cyclin E, activating the cyclin E-CDK2 complex, which further
phosphorylates Rb.  Presence of p27 and p21 inhibits cell cycle progression through
inactivation of cyclin/ CDK complexes.
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Typically, cdk inhibitors inhibit the activity of cyclin/cdk complexes thereby
negatively regulating cell cycle progression. [46].  However, at least one of the cdk
inhibitors identified, p21, plays a dual role functioning as either an assembly factor,
or an inhibitor, depending on the stoichiometry of the cyclin/cdk/p21 complex [47].
At low and intermediate concentrations, p21 functions as an assembly factor, while
at higher concentrations it acts as an inhibitor of cell-cycle progression.  Recently, it
has been shown that in vSMC p21 is necessary for PDGF-mediated vSMC
proliferation [48], thereby providing a framework for a dual role of p21 as both a
growth promoter and inhibitory factor.
1.6. Reactive Oxygen Species and Oxidative Stress
Reactive oxygen species (ROS) are highly reactive molecules, relative to
molecular oxygen, that are generated during cell metabolism as partially reduced
metabolites of oxygen. Many ROS possess unpaired electrons and thus are free
radicals.  These include molecules such as superoxide anion (O2•−), hydroxyl radical
(OH•), nitric oxide (NO•) and lipid radicals.  Other ROS, such as hydrogen peroxide
(H2O2), peroxynitrite (ONOO−) and hypochlorous acid (HOCl), are not free radicals
but contribute to oxidant stress [49].  The production of one ROS may lead to the
production of several others through radical chain reactions often involving lipid
molecules in the cell membrane. Lipid radicals produced through chain reactions,
and other ROS, affect cellular function in many ways including acting as cytotoxic
15
and mutagenic compounds and influencing intracellular signaling cascades that
modulate cell growth, differentiation and survival [3].  One of the well known effects
of ROS is the induction of oxidative damage to DNA resulting in strand breakage
and base and nucleotide modification [50].  This ultimately may result in genetic
mutations promoting the development of genotypically altered cells giving rise to the
benign neoplasm theory of atherosclerosis.
Potential enzymatic sources of ROS include mitochondrial respiration,
arachidonic acid metabolizing enzymes (lipoxygenase and cyclooxygenase),
cytochrome p450s, xanthine oxidase, NAD(P)H oxidases, and NO synthase [49,51].
Along with enzymatic sources, ROS can also be produced exogenously from
environmental chemicals, radiation, and ultraviolet light.  ROS have been
traditionally regarded as toxic by-products of metabolism with the potential to cause
damage to lipid, proteins, and DNA.  However, within the last few decades,
accumulating evidence suggests that ROS are essential messengers in cell signaling
and regulation [52].  It is essential, therefore, that ROS are maintained in a balanced
fashion so as to avoid disruption of the physiological functions of ROS by
pathological outcomes.
Fortunately, cells possess several antioxidant defense mechanisms that
combat the excessive accumulation of ROS [53].  Antioxidants either detoxify ROS
(glutathione (GSH) peroxidase, thioredoxin, superoxide dismutases, catalase), block
free radical chain reactions (vitamins A and C) or bind transition metals (transferrin).
Among the most important antioxidants is GSH (L-gamma-glutamyl-L
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cysteinylglycine), which reduces peroxides by the action of glutathione peroxidase
and is generated by NADPH-dependent glutathione reductase.  Small changes in the
ratio of GSH to GSSG (GSH disulfide) may have significant biological effects [54].
Thus oxidative stress can be defined as an imbalance between oxidant production
and the antioxidant capacity of the cell to prevent oxidative injury.  Oxidative stress,
or the shift in balance towards increased levels of ROS, has been implicated in a
large number of human diseases, including atherosclerosis (Table 1).
Some of the potential targets of ROS are noted in Table 1.  Of these targets,
ultimate outcomes of ROS activation include cellular growth/hypertrophy, survival
or apoptosis.  The entire class of MAP kinases, including the stress-activated protein
kinases (SAPKs - p38 and c-Jun-terminal kinase (JNKs)) and the extracellular
signal-regulated kinases (ERKs) are influenced by ROS with variable outcomes
depending on which  MAP kinase  is  activated [55,56].   Akt is a kinase  involved in
17
anti-apoptotic signaling that is regulated by ROS in angiotensin II-stimulated smooth
muscle cells [57].  Also, various caspase cascades are activated by ROS with
variable outcomes of cell survival or apoptosis [58].  In the above-mentioned
examples, the targets outlined may not be direct targets of ROS.  It is more likely
that increased levels of ROS de-activate tyrosine phosphatases which allow tyrosine
kinase activity to prevail leading to phosphorylation of their cellular targets,
including the ERKs and SAPKs [59].   One of the final outcomes of intracellular
signaling cascade activation is modulation of transcription factor binding to DNA.
NF-κB was the first transcription factor shown to respond directly to
oxidative stress [60].  Included among many of the other transcription factors
regulated by redox mechanisms are c-Fos, c-Jun, nrf-2 and AP-1 [61].  Many of
these transcription factors are involved in cell growth and differentiation.  Not only
are ROS implicated in cell growth, differentiation, and survival, ROS can also elicit
apoptosis and cell cycle arrest in vSMC [62,63]. Therefore, the response of vSMC to
ROS is variable with paradoxical effects and is likely dependent on the dose and
duration of exposure as well as the modulation of specific molecular targets.
18
TABLE 1
Sources of ROS, antioxidant defense mechanisms and potential targets.
ROS are endogenously generated inside cells by a variety of enzymes and are
increased by exogenous agents. The levels of intracellular ROS are balanced by
intracellular antioxidative defense mechanisms that consist of enzymatic and
nonenzymatic parts.  Potential signaling pathway targets of ROS are shown with
cellular outcomes noted (Adapted from [59] and [64]).
Sources of ROS
 Endogenous  Exogenous  
 NAD(P)H oxidase Environmental toxins  
 Mitochondria Ionizing radiation  
 Peroxisomes Ultraviolet light  
 Cytochrome P450 Electrical fields  
 Xanthine oxidase Chemotherapeutics  
 Cyclooxygenase Inflammatory cytokines  
 Lipoxygenase  
 
ΝΟ synthase
 
    
Antioxidant Defense Mechanisms
 Enzymatic  Nonenzymatic  
 Superoxide dismutase Glutathione  
 Catalase Thioredoxin  
 Glutathione peroxidase Vitamins C, A, E  
  Transferrin  
     
Targets of ROS
 
Growth/Hypertrophy
 
Survival
  
Apoptosis
 
 p38 ERKs  JNK  
 ERKs Akt  Caspases  
 Akt NF-κB   
   Caspases     
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During the past decade reduction-oxidation (redox) reactions that generate
ROS, including H2O2, O2- and OH-, have been identified as important chemical
mediators in the regulation of signal transduction processes involved in cell growth
and differentiation.  ROS ideally fulfill the prerequisites for intracellular signaling
molecules since they are rapidly generated, highly diffusible, easily degraded and
ubiquitously present in all cell types.  For example, H2O2 acts as a signaling molecule
through induction of the protooncogene c-fos resulting in vSMC growth.  It has
become clear that ROS stimulate early growth signals typical of mitogens, including
induction of c-fos and c-myc mRNA expression [65].
A variety of cytokines and growth factors that bind to receptors of different
classes have been reported to generate ROS in nonphagocytic cells.  This ligand-
mediated, or endogenous, production of ROS appears to regulate a large number of
signaling pathways.  For example, a number of growth factors that bind to tyrosine
kinase receptors have been shown to generate intracellular ROS essential for
mitogenic signaling.  In smooth muscle cells, ligand binding (eg. platelet derived
growth factor (PDGF)) to tyrosine kinase receptors results in the formation of H202
which is required for PDGF-induced tyrosine phosphorylation, ERK activation and
DNA synthesis [55].  Also, activation of G-protein coupled receptors, through
angiotensin II binding, activates NAD(P)H oxidase dependent ROS production in
smooth muscle cells causing activation of ERK and resultant cellular proliferation
[56].  However, exogenous ROS may also directly interact and activate cell surface
receptors, making kinase and phosphatase receptors targets of oxidative stress [52].
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Oxidant stress has recently been evaluated as a key factor in the development
of atherosclerosis and other cardiovascular diseases [51,66].  VSMC accumulation
and hypertrophy are characteristic of atherosclerotic, restenotic and hypertensive
vascular diseases.  The net balance between cellular proliferation and apoptosis
determines the extent of vSMC growth.   Increased levels of ROS have been shown
to shift vSMC from a contractile to a proliferative phenotype [9].  Evidence has also
been presented that ROS are required for growth factor stimulated proliferation of
smooth muscle [67].  The generation of reactive oxygen species (ROS) creates an
imbalance in cellular redox status that contributes to induction of proliferative vSMC
phenotypes [3]. Through activation of signaling cascades and redox-sensitive
transcription factors, many genes with important functional roles in the physiology
and pathophysiology of vascular cells are induced/repressed.  With ROS having the
capacity to activate pathways leading to growth/hypertrophy, cell survival or
apoptosis/growth arrest [59], a balance in the production and removal of ROS is
necessary to maintain normalcy in the vasculature.
1.7. Modulation of Vascular Smooth Muscle Cells by Allylamine
It is known that catecholamines cause a variety of vascular diseases [68].
Allylamine (3-aminopropene) is an aliphatic amine that is structurally similar to
endogenous catecholamines, although much simpler as it lacks a benzene ring.
Acting as a selective cardiovascular toxin, allylamine promotes the development of
smooth muscle cell lesions similar to those found in atherosclerotic vessels, and has
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been characterized as a model for chemically-induced atherosclerosis [69].
Allylamine has been used industrially in the past and has been known to be a cardiac
and vascular toxin since the 1940’s.
Earlier studies described the vascular lesions caused by allylamine to be
similar to early atherosclerosis because of the intimal smooth muscle cell
proliferation in smaller and medium-sized arteries [70].  More recent evidence
indicates subtle nonlethal changes in the vSMC are mediated through toxic
metabolites of allylamine resulting in medial hypertrophy and proliferation of vSMC
[69]. Data has now accumulated indicating that allylamine’s injurious effects on both
vSMC and the cardiac myocyte are dependent upon its deamination by a form of
amine oxidase, semicarbazide-sensitive amine oxidase (SSAO), a vascular specific
enzyme expressed predominantly in vSMC [71,72].  One of the molecular
mechanisms involved in allylamine toxicity is the generation of reactive oxygen
species [69]. Oxidative damage to the vascular wall by allylamine is mediated by
metabolic activation of the parent compound to acrolein and H202 by SSAO (Figure
5).  Both acrolein and hydrogen peroxide promote peroxidative injury, cellular
damage and gene deregulation [61,73,74].    Smooth muscle cells derived from aortas
of rats chronically exposed to allylamine maintain a proliferative advantage after
serial propagation in vitro over cells derived from control rats [69].  It is proposed
that phenotypic modulation of oxidatively stressed cells to a proliferative state
involves genetic reprogramming of growth signaling induced by oxidative chemical
injury.
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Figure 5:  Metabolism of allylamine to acrolein and hydrogen peroxide.
Acrolein and hydrogen peroxide induce cellular injury and repair pathways that
result in modulation of vSMC from a contractile to a synthetic/proliferative
phenotype.
Through activation of signaling cascades and redox-sensitive transcription
factors, many genes with important functional roles in the physiology and
pathophysiology of vascular cells are induced/repressed.  As shown previously in
this laboratory, vSMC that have undergone repeated cycles of oxidative chemical
injury display increased rates of proliferation compared to controls [75,76].   This
proliferative advantage is characterized by altered expression of integrin-associated
proteins and extracellular matrix interactions. Previous studies have identified a key
difference in secretion and extracellular matrix sequestration of several proteins,
including OPN, in oxidatively stressed cells compared to control cells [74,75].  OPN,
a secreted protein known to associate with the αvβ3 integrin, promotes both SMC
attachment and migration [77,78].  When the α v integrin subunit is blocked,
allylamine cells lose their proliferative advantage relative to control cells, suggesting
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that integrin mediated signaling may participate in the proliferative regulation of
oxidatively stressed vSMC [75].
Along with alteration of OPN in allylamine cells, the transcription factor, AP-
1, and NF-κB were increased in allylamine cells [75].  Inhibition of NF-κB by
pyrrolidine dithiocarbamate (PDTC) selectively compromised proliferation of
allylamine cells, while seeding of allylamine cells on a collagen matrix decreased
inducible NF-κB binding to control cell levels following mitogen stimulation
[Williams, ES and Ramos, KS, personal communication]. These results further
implicate ECM interactions in the deregulation of vSMC proliferation following
oxidative injury.  Other alterations that are involved in the increased proliferative
capacity of allylamine cells include enhanced phosphatidylinositol metabolism
[69,79] and increased c-Ha-ras proto-oncongene expression [74,79].
Phenotypic modulation of vSMC by allylamine has been characterized, as
outlined above.  Yet, intracellular signaling pathways involved in the proliferative
phenotype of oxidatively injured vSMC (allylamine cells) have not been clarified.
Through evaluation of ERK activation and the expression profiles of cell cycle
regulatory proteins, molecular mechanisms contributing to the proliferative vSMC
phenotype induced by oxidative stress may be elucidated.
1.8. Research Objectives
The intent of this research is to characterize interactions between oxidative
injury and key intracellular signaling pathways that may be involved in integrin-
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extracellular matrix (ECM) coupled signaling in modulation of vSMC phenotype.
Previous studies in this laboratory have shown a proliferative advantage of
oxidatively injured vSMC over control counterparts when grown on a plastic
substrate.  This advantage is lost when cells are grown on collagen, a growth
inhibitory substrate [76].  The intracellular signaling pathways involved in
modification of oxidatively stressed cells have yet to be elucidated.  Thus, this
research will begin to delineate the signaling pathways that contribute to the altered
proliferative rate of oxidatively injured vSMC.   The hypotheses to be tested include:
1) Oxidatively injured vSMC will exhibit changes in expression of cell cycle
regulatory proteins and growth matrix will modulate these alterations.  2) Matrix
dependent regulation of phosphorylated extracellular regulated kinases (ERK1/2)
will contribute to the proliferative advantage of oxidatively injured vSMC through
modulation of cell cycle regulatory proteins. Four specific aims were examined,
including:
1.  Examination of matrix dependent alterations in the cell cycle regulatory
proteins, p27 and p21, in random cycling, G1 synchronized, and mitogen
released allylamine cells compared with control counterparts.
Experiments were designed to determine the basal expression profiles of select
cell cycle regulatory proteins in allylamine and control cells.  Flow cytometry
was utilized to determine cycling percentage of cells in various experimental
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setups.  The contribution of growth substrate to cell cycle protein expression
levels was determined through seeding cells on plastic or collagen growth
substrates.  Protein levels were identified using SDS-PAGE followed by western
blot analysis.
2. Characterization of ERK activation profiles in allylamine versus control cells
when grown on both plastic and collagen.
To determine the involvement of the ERK signaling pathway in regulation of the
proliferative phenotype of oxidatively stressed cells, experiments were conducted
evaluating time dependent mitogen activation of ERKs in allylamine and control
cells.  Matrix dependency was also evaluated through growth on the different
extracellular matrix substrates, plastic or collagen.
3. Determination of the contribution of ERK activation to the altered expression
levels of cell cycle regulatory proteins in allylamine cells.
Through the use of the MEK1/2 inhibitor, U0126, alterations in cell cycle
regulatory proteins were evaluated following inhibition of ERK activation.
These studies were designed to assess the contribution of ERKs to differential
cell cycle regulatory protein expression profiles in oxidatively stressed vSMC.
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4 .  Investigation of the role of antioxidant administration (PDTC) in the
alteration of cell cycle regulatory proteins.
The cell model utilized in these experiments is thought to result in atherogenesis
due to oxidative stress following allylamine metabolism to acrolein and H2O2.
Allylamine and control cells were grown in the presence and absence of PDTC to
determine if this antioxidant would normalize cell cycle regulatory protein
expression in oxidatively stressed vSMC.
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CHAPTER II
MATERIALS AND METHODS
2.1. Reagents
Cell culture reagents were purchased from Gibco/Invitrogen (Carlsbad, CA).
Fetal bovine serum (FBS) was obtained from Hyclone (Logan, UT).  Products from
Sigma (St. Louis, MO) include NaCl, NaF, EDTA, Na pyrophosphate, Na
orthovanadate, glycerol, and PDTC.  Protease inhibitor cocktail, phosphatase
inhibitor cocktail, dithiotreitol and propidium iodide were obtained from Calbiochem
(San Diego, CA). RNase A was purchased from Worthington Biochemicals,
(Lakewood, NJ).  Bovine serum albumin (BSA) was purchased from Amersham
Biosciences; USBiochemical (Piscataway, NJ).  Control cell lysates including A431
EGF stimulated cell lysate and 3T3 nonstimulated cell lysate were purchased from
Upstate Biotechnologies (Lake Placid, NY). U0126 (MEK1/2 inhibitor) was
purchased from New England Biolabs (Beverly, MA).  Supersignal, Superblock
and Restore were purchased from Pierce Chemical (Rockford, IL).  Type I collagen
(rat tail collagen) coated plates were obtained from Becton Dickinson (Franklin
Lakes, NJ).  All other reagents for SDS-PAGE and western blotting were from Bio-
Rad (Hercules, CA).
Primary antibodies were purchased from New England Biolabs, Beverly, MA
(rabbit polyclonal anti-phosphorylated ERK1/2), Upstate Biotechnologies, Lake
Placid, NY (rabbit polyclonal anti-total ERK1/2), Advance Immunochemical
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Incorporated, Long Beach, CA (mouse monoclonal anti-GAPDH) and Santa Cruz
Biotechnologies, Inc., Santa Cruz, CA (rabbit polyclonal anti p21, p27, and cdk2).
Secondary antibodies used were donkey anti-rabbit and donkey anti-mouse
horseradish peroxidase conjugated IgGs obtained from Jackson (West Grove, PA).
2.2. Cell Culture
Vascular smooth muscle cells were isolated by successive enzymatic
digestion of the aortas from adult male Sprague-Dawley rats gavaged with
allylamine-HCl (70 mg/kg- allylamine cells) or tap water (control cells) daily for 20
days as previously described [69].   This dosing regimen is associated with
permanent modulation of vSMC toward a highly proliferative, mitogen-responsive
state.  Subcultures were prepared by trypsinization of subconfluent cultures and
maintained in Medium 199 supplemented with 10% FBS, and 1%
penicillin/streptomycin in 5% CO2:95% air at 37°C. Cell  cultures between passage
levels 20-24 were used in all experiments.
2.3. U0126 (MEK1/2 Inhibitor)
Cell cultures were grown to 70% confluence at which time they were washed
twice with 1X phosphate buffered saline (PBS) followed by mitogen restriction
(0.5% FBS in Medium 199) for 48 hours. Serum restricted cultures were then
pretreated with U0126, an inhibitor of MEK1/2 activation (25 µM), in media
containing 0.5% FBS for 30 min, followed by addition of media containing 10%
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FBS and various concentrations of U0126 for 9 hr. At this time, cultures were
harvested for protein extraction followed by SDS-PAGE/Western blot analysis.
2.4. Pyrrolidine Dithiocarbamate
Cell cultures were grown to 70% confluence at which time they were washed
twice with 1X phosphate buffered saline (PBS) followed by mitogen restriction
(0.1% FBS in Medium 199) for 48 hours. Synchronized cultures were then pretreated
with PDTC (25 or 100 nM) in media containing 0.1% FBS for 2 hr, followed by
addition of media containing 10% FBS and various concentrations of PDTC, an
inhibitor of NF-κB activation [80], for 9 hr. At this time, cultures were harvested for
protein extraction followed by SDS-PAGE/ Western blot analysis.
2.5. SDS-PAGE and Western Blot Analysis
Cells were lysed in buffer containing 20 mM Tris-Cl (pH 7.4), 50 mmol/L
NaCl, 50 mmol/L NaF, 50 mmol/L EDTA, 20 mmol/L Na pyrophosphate, 1% Triton
X-100, protease inhibitor cocktail containing 0.5 mmol/L AEBSF (4-(2-
aminoethyl)benzene-sulfonylfluoride HCl), 150 nmol/L aprotinin, 2 µM E-64
protease inhibitor, 0.5 mmol/L EDTA and 1 µmol/L leupeptin and phosphatase
inhibitor cocktail containing 2 mmol/L imidazole, 1 mmol/L NaF, 1.15 mmol/L Na
molybdate, 1 mmol/L Na orthovanadate and 4 mmol/L Na tartrate dihydrate.  The
lysate was frozen, thawed and cleared by centrifugation.  Protein concentration was
determined using a BCA protein assay (Pierce Chemical, Rockford, IL).
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Prior to electrophoresis, protein (2-10µg) was added to 2X sample buffer (0.5
mol/L Tris-Cl (pH 6.8), 75% glycerol, 50 mmol/L dithiothreitol, 0.05% bromophenol
blue, and 5% SDS) and boiled for 5 minutes.  Proteins were separated by SDS-
PAGE using a 9.5-16% (w/v) gel.  Proteins were electroblotted to a nitrocellulose
membrane and blocked with 5% nonfat dry milk, washed and incubated with
appropriate antibody.  Blots were washed and incubated with horseradish peroxidase
conjugated secondary antibody followed by Supersignal reagent and exposed to x-
ray film.   Phosphorylated ERK1/2 antibodies were removed from the membranes
with Restore stripping reagent and reprobed with anti-total ERK1/2 antibody to
verify loading.  p21, p27,and cdk2  antibodies were removed from the membranes
with Restore stripping reagent and reprobed with mouse monoclonal anti-GAPDH
antibody to verify loading.  Densitometry was performed on signals detected on the
developed film using Multianalyst software (Bio-Rad, Hercules, CA).
2.6. Phosphorylated Antibodies
Due to the nature of phosphorylated antibodies and their specificity for
phosphorylated residues, it was necessary to optimize for western blot analysis.  In
order to visualize phosphorylated ERK1/2, the phosphorylated antibody was diluted
in Superblock  prior to membrane incubation.  When 5% nonfat dry milk was
utilized, signal was dramatically diminished due to the interaction of the
phosphorylated milk proteins with the phosphorylated antibody.  Also, it was
necessary to filter the secondary antibody by diluting it in a small volume of
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Superblock followed by filtration through a 0.2 micron filter.  The filtrate was
diluted to its final concentration in 5% nonfat dry milk followed by membrane
incubation.  The remainder of the protocol was followed as outlined in section 2.5.
2.7. Flow Cytometry
Cell cultures were grown to 70% confluence followed by cell
synchronization for 48 hr using media containing 0.1% or 0.5% FBS.  At 3 hr
intervals, cultures were harvested to determine cell cycle progression utilizing flow
cytometry.  Ethanol fixation and propidium iodide staining of cell suspensions was
followed as outlined in Cells: A Laboratory Manual [81].  Briefly, cells were
trypsinized and washed twice in 1XPBS + 1% BSA.  Cells were counted and fixed in
5 ml of cold (-20 °C) ethanol.  Propidium iodide staining was accomplished by
centrifugation of the fixed cell suspension and removal of ethanol followed by
washing twice with 1XPBS + 1% BSA.  Cells were resuspended in 1XPBS +1%
BSA.  Propidium iodide (50 µg/ml prepared in 0.038M sodium citrate pH 7.0) and
RNase A (1 mg/ml prepared in 10mM Tris-HCl, pH 7.5) were added to the
resuspended cells.  The cell suspension was incubated at 37 ° C for 30 minutes.
Samples were immediately processed using a FACS Calibur apparatus (Becton
Dickinson, Franklin Lakes, NJ) with ModFit software (Verity Software House,
Topsham, ME) for data analysis.
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2.8. Statistics
Results are expressed as the mean ± SE.  Statistical significance was assessed
by Student’s unpaired two-tailed t test or analysis of variance followed by
comparison of group averages by Fisher’s LSD analysis, using the StatView
statistical program (SAS Institutes Inc., Cary, North Carolina).  Symbols denote
statistically significant differences at the p<0.05 level.
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CHAPTER III
RESULTS
3.1. Differential Regulation of p27 and p21 in Cycling Control and Allylamine
Cells
Oxidatively stressed vSMC isolated from allylamine-treated rats are
characterized by enhanced mitogenic sensitivity and increased rates of proliferation
when seeded on plastic or fibronectin substrates, but not collagen [76].  To evaluate
the involvement of cyclin dependent kinase inhibitors in the regulation of matrix-
modulated proliferation, protein lysates were harvested from cycling control and
allylamine cells.  Flow cytometric analysis with propidium iodide staining was used
to evaluate the percentage of cells in each phase of the cell cycle (Figure 6). The cell
populations were determined to be randomly cycling cells (Table 2).
In cycling cell populations, no significant differences in p27 levels were
observed under any of the experimental conditions examined.  p21 protein was
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increased in allylamine cells seeded on plastic compared to control cells (1.60 ± 0.12
fold increase), while comparable levels of p21 were observed in control and
allylamine cells on a collagen substrate (Figure 7).  Elevated p21 levels were
observed in control cells grown on collagen compared to growth on plastic.  The
increase in the p21 allylamine/control ratio when cells were grown on a plastic
substrate is significant (p<0.05) when compared to cells grown on a collagen
substrate (Figure 8).   These findings are consistent with the loss of proliferative
advantage of allylamine cells compared to control cells when seeded on a collagen
substrate [76]. Membranes were stripped and reprobed with anti-GAPDH, and anti-
cdk2 to confirm equal protein loadings (Shown in Figure 7).
3.2. Differential Expression of p27 and p21 Following Serum Stimulation in G0
Synchronized Control and Allylamine Cells
Next, p27 and p21 expression was examined in G0 synchronized cells before
and after challenge with serum to induce cell cycle progression.  G0 synchronization
(0 hour) was achieved by serum restriction in 0.1% FBS for 48 hours, and confirmed
with propidium iodide staining of fixed cell suspensions (Figure 9).  Confirmation of
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Figure 6:  Flow cytometry of randomly cycling control and allylamine cells.
Representative flow cytometry of propidium iodide stained fixed cells following 48
hr of serum deprivation (0.5%) showing inadequate cell synchronization (n=3).
TABLE 2
Inadequate G0 synchronization in control and allylamine cells.  Data is
represented as average percentage of cells (SEM)  (n=3).
Phase of Control Allylamine
Cell Cycle % (SEM) % (SEM)
   
G0/G1 63.3  (1.4) 63.4  (5.7)
   
   
S 23.2  (1.9) 18.2  (1.9)
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Figure 7: Differential regulation of p27 and p21 in cycling control and
allylamine cells. Control (C) and allylamine (AAM) cells were grown to 70%
confluence on plastic or collagen.  Following serum deprivation (0.5% FBS) for 48
hours, cell lysates were prepared.  Western blots of p27 and p21 proteins with
control blots of GAPDH (p36) and cdk2 (p34) are depicted.  These blots are
representative of 3 or 4 replicates for p27 and p21, respectively, from at least two
independent experiments.
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Figure 8:  Collagen effects on p27 and p21 expression levels in randomly
cycling control and allylamine cells.  Graph of average fold differences of band
densities between allylamine and control lysates for randomly cycling populations.
This represents the average of 3 or 4 replicates for p27 and p21, respectively, from at
least two independent experiments.  Error bars represent standard error of the mean.
 p<0.05 for comparison of p21 plastic versus collagen.
cell cycle progression was accomplished by addition of 10% serum to G0
synchronized cells for 18 hr, which reduced the G0/G1 population and caused
proportional increases in S phase cells (Table 3).
p27 and p21 were higher (1.83 ±  0.36 and 1.77 ±  0.19 fold increase,
respectively) in G0 synchronized allylamine cells seeded on a plastic substrate
relative to controls (Figure 10).  When cells were grown on a collagen substrate, p27
and p21 in allylamine cells were comparable to levels in control cells. Levels of p27
and p21 for both cell types grown on collagen were elevated over levels observed
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when control cells were grown on plastic.  In both cell types, p27 levels decreased as
cells progressed through G1 when cells were grown on either substrate, but this
difference was most pronounced on a collagen substrate.  p21 levels increased as the
cells cycled, irrespective of the growth substrate.  Interestingly, no differences in the
levels of p27 or p21 were observed between the two cell types following serum
stimulation irrespective of the seeding substrate.  The ratio of allylamine/control
average band densities for p27 and p21 were significantly increased in G0
synchronized cells when grown on plastic compared with growth on collagen or
following 9 hours of mitogen stimulation (Figure 11).  These results suggest that
increased p27 and p21 in allylamine cells may play a role in regulation of the
proliferative advantage of oxidatively injured vSMC on plastic.
TABLE 3
Confirmation of G0 synchronization and cell cycle progression in control and
allylamine cells.  Data is represented as average percentage of cells (SEM)  (n=3).
Phase of Control Allylamine
Cell Cycle 0 h 18 h 0 h 18 h
     
G0/G1 75.2 (3.3) 36.0 (5.9) 73.3 (3.2) 46.3 (6.6)
     
     
S 16.6 (3.4) 62.9 (4.9) 12.2 (2.9) 53.5 (6.6)
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Figure 9:  Flow cytometry of G0 synchronized and cell cycle released control
and allylamine cells. To determine cell cycle synchronization and progression, cells
were harvested every 3 hrs following mitogen stimulation (10% FBS) in serum
restricted (0.1% FBS) cultures.  Ethanol fixation, propidium iodide staining and flow
cytometry were performed.  0 hr time point represents cell populations following 48
hr of serum deprivation (0.1%).  18 hr time point represents mitogen stimulation
(10%FBS) for 18 hr in serum restricted populations.  The results shown are
representative of 3 independent experiments.
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Figure 9: Continued
.
Figure 10: Differential expression of p27 and p21 in G0 synchronized and cell cycle released
control and allylamine cells.  Control and allylamine cells were grown to 70% confluence on plastic
or collagen.  Following serum deprivation (0.1% FBS) for 48 hours, cell lysates were prepared at 0 hr
and 9 hr following serum stimulation. Western blots of p27 and p21 that are shown are representative
of at least two independent experiments.
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Figure 11:  Effects of collagen and mitogen stimulation on p27 and p21
expression levels in control and allylamine cells. Graphic representation of average
fold differences in band densities between serum restricted (0.1% FBS) allylamine and
control lysates, grown on plastic or collagen, at 0 hr and 9 hr following mitogen
stimulation (10% FBS).  This represents the average of 4 or 3 replicates for p27 and
p21, respectively, from at least two independent experiments. Error bars represent
standard error of the mean.  p<0.05 for comparison of p27 (plastic, 0h) versus other
experimental groups. # p<0.05 for comparison of p21 (plastic, 0h) versus other
experimental groups.
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3.3. Effect of PDTC Treatment on p27 and p21 Expression in Control and
Allylamine Cells
NF-κB is involved in the matrix-dependent regulation of the atherogenic
vSMC phenotype following oxidative injury [76].  Inhibition of NF-κB by the
antioxidant PDTC selectively nullifies the proliferative advantage of allylamine
cells.  To determine if a functional link exists between the p27 and p21 cdk inhibitors
and NF-κB signaling in the regulation of vSMC proliferation, protein lysates were
harvested from allylamine and control cells following mitogenic stimulation of
growth arrested cultures seeded on plastic or collagen in the presence or absence of
25 and 100 nM PDTC. Similar to the effect of seeding cells on a non-permissive
collagen substrate, 100 nM PDTC pre-treatment increased p27 and p21 levels in G0
synchronized control cells seeded on a plastic substrate.  There was no effect of
PDTC pre-treatment on p27 or p21 levels in G0 synchronized allylamine cells on
either matrix and in G0 synchronized control cells seeded on a collagen substrate
(Figure 12).
Serum stimulation for 9 hr decreased p27 and increased p21 expression in
both cell types grown on plastic or collagen.  The decrease in p27 was further
suppressed by 100 nM PDTC treatment when cells were grown on collagen.   The
higher concentration of PDTC did not have an effect on p21 levels in control and
allylamine cells as cells progressed through the cell cycle.  These results indicate
oxidatively injured vSMC show upregulation of p27 and p21 levels under quiescent
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conditions; following cell cycle progression, allylamine levels normalize to control
levels when cells are grown on plastic.  In contrast, growth on a collagen matrix
results in comparable p27 and p21 levels in control and allylamine cells both in G0
synchronized and cycling populations. Our results also show that following cell
cycle progression, p27 protein decreases while p21 protein increases in control and
oxidatively injured vSMC.  This supports the hypothesis that p21 is growth
promotive in oxidatively injured vSMC.  On collagen, in the presence of PDTC and
mitogen stimulation, p27 levels are further decreased in control and allylamine cells
while PDTC and mitogen stimulation appear to increase p21 levels in both cell types.
Figure 12: Effects of antioxidant administration on cdk inhibitors in control
and allylamine cells.  Cells were grown to 70% confluence on plastic or collagen.
Following serum deprivation (0.1% FBS for 48 hours), 2 hr pretreatment (media
change only or 100nM PDTC) was followed by serum stimulation with or without
100nM PDTC.  Western blots of p27 and p21 that are shown are representative of at
least two independent experiments.
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Response differences between cell types was determined by evaluating the
ratio of allylamine/control average band densities (Figures 13 and 14).  When PDTC
was administered at the higher concentration of 100 nM, the allylamine/control ratio
for p21 and p27 was significantly increased (p<0.05) in G0 synchronized cells grown
on plastic.  In cycling cells, in the presence of 100 nM PDTC, the ratio of
allylamine/control for p27 protein was significantly decreased (p<0.05) in cells
grown on both plastic and collagen compared to all other treatment groups (Figure
13).  In contrast, this ratio for p21 protein was significantly decreased (p<0.05) when
cells were grown on collagen only (Figure 14).  As shown by this data, PDTC
treatment in the presence of mitogen stimulation had a more pronounced effect on
p21 expression in allylamine cells compared with control cells when grown on a
collagen substrate.  These results provide further evidence that altered p21
expression may provide the matrix dependent proliferative advantage of oxidatively
injured vSMC.
When the lower concentration of PDTC (25 nM) was administered in a
similar manner as outlined in the above experiments, smaller differences were
observed (Figures 15 and 16).  For p27, a significant decrease in the
allylamine/control ratio was observed (p<0.05) when cells were grown on collagen
in the presence of PDTC and mitogen stimulation compared with all other treatment
groups except PDTC pre-treatment on both plastic and collagen (Figure 15).  As
well, a significant decrease (p<0.05) in the allylamine/control ratio was observed in
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G0 synchronized cells both in the presence and absence of PDTC when cells were
grown on collagen. No other significant differences were observed for p27.  p21
showed no significant differences between treatment groups following 25nM PDTC
administration (Figure 16).  However, a decreasing trend in the allylamine/control
ratios following mitogen stimulation was observed following mitogen stimulation in
the presence and absence of 25 nM PDTC, consistent with a dose dependence of the
response to PDTC.
Figure 13:  Effect of 100 nM PDTC treatment on p27 expression in control
and allylamine cells. Control and allylamine cells were grown to 70% confluence on
plastic or collagen. Following serum deprivation (0.1% FBS, 48 hours), 2 hr
pretreatment (media change only or 100nM PDTC) was followed by serum
stimulation with or without 100nM PDTC.  Cell lysates were prepared at 0 hr
(following pretreatment) and 9 hr following serum stimulation. Graphic
representations of p27 densitometric band ratios of allylamine/control are shown.
Graph represents the average of 4 replicates from at least two independent
experiments. Error bars represent standard error of the mean.  p<0.05 for
comparison of plastic (0h) versus all other experimental groups. # p<0.05 for
comparison of PDTC treated (9h, plastic) versus all other experimental groups.
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Figure 14:  Effect of 100 nM PDTC treatment on p21 expression in control
and allylamine cells. Control and allylamine cells were grown to 70% confluence on
plastic or collagen. Following serum deprivation (0.1% FBS, 48 hours), 2 hr
pretreatment (media change only or 100nM PDTC) was followed by serum
stimulation with or without 100nM PDTC.  Cell lysates were prepared at 0 hr
(following pretreatment) and 9 hr following serum stimulation. Graphic
representations of p21 densitometric band ratios of allylamine/control are shown.
Graph represents the average of 3 replicates from at least two independent
experiments. Error bars represent standard error of the mean.   p<0.05 for
comparison of plastic (0h) versus all other experimental groups. # p<0.05 for
comparison of PDTC treated (9h, collagen) versus all other experimental groups.
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Figure 15: Effect of 25 nM PDTC treatment on p27 expression in control
and allylamine cells. Control and allylamine cells were grown to 70% confluence on
plastic or collagen. Following serum deprivation (0.1% FBS, 48 hours), 2 hr
pretreatment (media change only or 25 nM PDTC) was followed by serum
stimulation with or without 25 nM PDTC.  Cell lysates were prepared at 0 hr
(following pretreatment) and 9 hr following serum stimulation. Graphic
representations of p27 densitometric band ratios of allylamine/control are shown.
Graph represents the average of 4 replicates from at least two independent
experiments. Error bars represent standard error of the mean.  * p<0.05 for
comparison of plastic (0h) versus collagen (0h) and PDTC treated (0h, collagen).  #
p<0.05 for comparison of PDTC treated (9h, collagen) versus plastic (9h), collagen
(9h) and PDTC treated (9h, plastic).
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Figure 16: Effect of 25 nM PDTC treatment on p21 expression in control
and allylamine cells. Control and allylamine cells were grown to 70% confluence on
plastic or collagen. Following serum deprivation (0.1% FBS, 48 hours), 2 hr
pretreatment (media change only or 25 nM PDTC) was followed by serum
stimulation with or without 25 nM PDTC.  Cell lysates were prepared at 0 hr
(following pretreatment) and 9 hr following serum stimulation. Graphic
representations of p21 densitometric band ratios of allylamine/control are shown.
Graph represents the average of 3 replicates from at least two independent
experiments. Error bars represent standard error of the mean.  * p<0.05 for
comparison of plastic (0h) versus collagen (0h) and PDTC treated (0h, collagen). *
p<0.05 for comparison of collagen (0h) and PDTC treated (0h, plastic) with plastic
(9h) and PDTC treated (9h, collagen).
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3.4. Differential ERK1/2 Activation of Control and Allylamine Cells
The activation of ERK1/2 is an important signaling cascade for passage of a
cell from G1 to S phase of the cell cycle [41]. ERK1/2 activation is vital for
continued cyclin D1 protein expression in late G1 [38].  Cyclin D1 complexes with
cdk4/6 for phosphorylation of the retinoblastoma protein followed by induction of
E2F-regulated genes, including cyclin A [39].  These interactions allow transition of
a cell from G1 to S phase of the cell cycle.  To determine the involvement of ERK1/2
activation in regulation of proliferation in vSMC, protein lysates were harvested
from allylamine and control cells following time dependent FBS stimulation of
mitogen restricted cultures grown on plastic and collagen.  ERK1/2 activation
peaked 15 min post-stimulation in both control and allylamine cells, as determined
by western blot analysis using anti-phosphorylated ERK1/2 antibodies (Figure 17).
Peak activation was increased in allylamine cells versus controls when cells were
grown on plastic, and this difference was lost in cells grown on a collagen substrate.
Comparable ERK1/2 loadings were confirmed by stripping and reprobing
membranes with anti-total ERK1/2 (Fig 18).
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Figure 17:  Differential ERK1/2 activation of control and allylamine cells.
Control and allylamine cells were grown to 70% confluence on plastic or collagen.
Following serum deprivation for 48 hours, cultures were stimulated with media
containing 10% FBS.  Cell lysates were prepared at 0, 15, 30, 60, 120, and 240
minutes following exposure to serum.  (CNTL-control lysates; AAM-allylamine
lysates; + positive control, serum stimulated 3T3 lysates; - negative control,
nonstimulated 3T3 lysates).  Immunoblots of anti-phosphorylated ERK1/2 on plastic
and collagen are shown.   Membrane was stripped and reprobed with anti-total
ERK1/2 to verify equal ERK1/2 loadings (results shown in Figure 17).
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Figure 18:  Confirmation of equal ERK1/2 protein loading.  Control and
allylamine cells were grown to 70% confluence on plastic or collagen.  Following
serum deprivation for 48 hours, cultures were stimulated with media containing 10%
FBS.  Cell lysates were prepared at 0, 15, 30, 60, 120, and 240 minutes following
exposure to serum.  (CNTL-control lysates; AAM-allylamine lysates; + positive
control, serum stimulated 3T3 lysates; - negative control, nonstimulated 3T3 lysates).
Immunoblots of anti-total ERK1/2 on plastic and collagen are shown.
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As both the degree and duration of ERK1/2 activation are important in cell
growth and proliferation, evaluation of ERK1/2 following prolonged mitogen
stimulation was examined. Allylamine cells maintained increased ERK1/2 activation
for a longer duration than control cells when grown on either plastic or collagen.
Further evaluation of the differential matrix and time dependent profile of
ERK1/2 activation in allylamine and control cells consisted of examining band
density ratios of allylamine/control cells (Figures 19 and 20).  Growth on both plastic
and collagen resulted in higher peak phosphorylation of ERK1/2 at 15 and 30 min
(approximately 3.5 fold increase) followed by return to control levels at 60 min in
allylamine cells compared to control cells.  The second wave of activation, occurring
at 120 and 240 min, was also higher in allylamine cells compared with control
counterparts.  However, this increase was not as dramatic as was observed when
cells were grown on plastic (two-fold increase only) (Figure 19).  In contrast, when
cells were grown on collagen, the activation profile of ERK1/2 ratios showed a
gradual increase with peak differences observed at 140 min (approximately 12-fold
difference in allylamine over control ratios).  Early ERK1/2 activation was still
increased in allylamine versus control cells when grown on collagen, however, this
difference was only slightly less than two fold (Figure 20).  These data suggest that
differences in ERK activation profiles play a key role in altered proliferation of
oxidatively injured vSMC.
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Figure 19: ERK1/2 activation profile of control and allylamine cells grown
on plastic.  Control and allylamine cells were grown to 70% confluence.  Following
serum deprivation for 48 hours, cultures were stimulated with media containing 10%
FBS.  Cell lysates were prepared at 0, 15, 30, 60, 120, and 240 minutes following
exposure to serum. Graphic representations of phosphorylated p44 (ERK1) and
phosphorylated p42 (ERK2) densitometric band ratios of allylamine/control are
shown.
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Figure 20: ERK1/2 activation profile of control and allylamine cells grown
on collagen.  Control and allylamine cells were grown to 70% confluence.
Following serum deprivation for 48 hours, cultures were stimulated with media
containing 10% FBS.  Cell lysates were prepared at 0, 15, 30, 60, 120, and 240
minutes following exposure to serum. Graphic representations of phosphorylated p44
(ERK1) and phosphorylated p42 (ERK2) densitometric band ratios of
allylamine/control are shown.
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3.5. Effect of  MEK1/2 Inhibition on p27 and p21 Expression in Control and
Allylamine Cells
Figure 21:  Effect of MEK1/2 inhibition on p27 and p21 expression in
control and allylamine cells. Control and allylamine cells were grown to 70%
confluence on plastic or collagen. Following serum deprivation for 48 hours,
pretreatment for 30 min (media change only or 25µM U0126) was followed by
serum stimulation with or without U0126 (25µM).  Cell lysates were prepared at 9 hr
following serum stimulation. Western blots of p27 and p21 protein lysates are shown
and represent at least two independent experiments.
Given observed differences in matrix dependent alterations in peak ERK1/2
activation in allylamine cells, we investigated a possible functional link between
ERK1/2 activation and cdk inhibitor expression.  Protein lysates were harvested from
allylamine and control cells seeded on either plastic or collagen following serum
stimulation for 9 hours in the presence or absence of 25µM U0126, a MEK1/2
inhibitor. MEK1/2 inhibition increased p27 levels in both control and allylamine
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cells irrespective of the seeding substrate (Figure 21).  No differences in p27
induction were observed between the two cell types, suggesting that differences
observed in p27 expression in oxidatively injured vSMC are not dependent on MAP
kinase activation.  In contrast, cell type-specific differences in p21 expression were
observed following inhibition of MEK1/2 (Figure 22).  U0126 reduced p21
expression in both cell types, but the response was markedly enhanced in allylamine
cells, and preferentially observed on a restrictive collagen substrate (Figures 21 and
22).  These data suggest the involvement of ERK1/2 activity in matrix dependent
modulation of p21 levels in oxidatively injured vSMC.
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Figure 22: MEK1/2 inhibition by U0126 in control and allylamine cells. Graphic
representation of fold differences in densitometric band ratios between serum
restricted (0.1% FBS) allylamine and control lysates, grown on plastic or collagen (9
h) following mitogen stimulation (10% FBS) with or without U0126 (25 µM).
Graphs represent the average of at least two independent experiments. Error bars
represent standard error of the mean.
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CHAPTER IV
DISCUSSION AND SUMMARY
4.1. p27 and p21 Expression in Allylamine and Control Cells
Phenotypic modulation of vSMC by chronic oxidative stress induced with
allylamine differentially modulates profiles of surface integrin expression [75].
Expression of α1 and α5 integrin subunits are substantially reduced on allylamine
cells, while expression of β3 integrin is increased compared to control cells.  Thus,
the proliferative advantage seen in oxidatively stressed vSMC may be mediated by
alterations in integrin-coupled signaling.  This interpretation is supported by studies
showing extracellular matrix-dependent differences in allylamine cell proliferation
compared to control cells [76].  The proliferative advantage of allylamine cells is
maintained when cells are grown on plastic, pronectin or fibronectin, but lost when
grown on collagen, a ligand for the β1 integrin subunit [76]. Consistent with these
observations, Thyberg’s group has previously shown that the substrate is a crucial
factor in the progression of vSMC from contractile to synthetic/proliferative
phenotypes [12].  Smooth muscle cells propagated on both laminin and collagen IV
maintained contractile phenotypes longer than cells propagated on fibronectin and
vitronectin, which promoted conversion to proliferative phenotypes.
To further explore the nature of integrin/ECM signaling in oxidatively
stressed vSMC, we first evaluated the expression of the cdk inhibitors, p27 and p21,
59
in cycling allylamine and control vSMC cultured on plastic or collagen substrates.
Alterations in cell cycle progression leading to increased proliferative rates are
highly dependent on the activity of the cyclin dependent kinases.  One mechanism of
cdk regulation is through the binding of cdk inhibitors to the cyclin/cdk complex
[82]. In mammalian cells, there are two families of cdk inhibitors known: the INK4
family, consisting of p16 and p15, and the Kip/Cip family including p27 and p21.
The INK4 family is specific for inhibition of cdk4 and cdk 6 complexes thereby
inhibiting cyclin D associated cdk activity; while p27 and p21 are general cdk
inhibitors inactivating both cyclin D and cyclin E associated cdk activity [83].  p27
has been implicated in mediating TGF-β- and contact-induced inhibition of vSMC
proliferation [84], as well as inhibiting vSMC and fibroblast proliferation and
migration [85].  VSMC growth on polymerized collagen inhibits downregulation of
p27, thereby inhibiting S-phase entry [86].  p27, therefore, acts primarily in the
context of inhibition of cell cycle progression.
  In contrast, p21 appears to have a multiplicity of functions in regulation of
cell cycle control. p21 has dual functions as a cell cycle inhibitor [87,88], and as a
permissive element for cell cycle progression in PDGF-stimulated vSMC [48].
Mechanisms through which p21 modulates cell cycle progression include the
inhibition of cyclin/cdk complex phosphorylation, and direct inhibition of the
transcription factor E2F.  Permissive effects of p21 include promotion of cyclin/cdk
complex assembly and nuclear localization through action as an adaptor protein,
inhibition of apoptosis, and interaction with a number of transcription factors
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including CEBP and NF-κB that are implicated in responses to oxidative stress
[46,47,87].
In vSMC the process of growth inhibition is complex and can result in three
outcomes depending on the combination of stimuli to which the cells are exposed:
quiescence, hypertrophy or apoptosis [89].  For example, p27 induction after
angiotensin treatment is associated with hypertrophy, whereas, serum-induced
reduction in p27 is associated with proliferation [90].  These paradigms are
indicative of the complex phenotypes that vSMC can exhibit both in vivo and in
vitro, and the complexity of regulation of cdk inhibitors and their role in regulating
vSMC phenotypic modulation.
Alterations in p27 and p21 expression have been implicated in the
pathogenesis of vascular disease.  VSMC ultimately undergo alterations in cell cycle
progression leading to the vasculoproliferative response of many vascular diseases,
including atherosclerosis [89].  Differential expression of p27 and p21 has been
observed in human atherosclerotic arteries [91].  p27 was shown to be constitutively
expressed in normal and atherosclerotic arteries, whereas p21 was elevated in human
atherosclerotic arteries and undetectable in normal counterparts.  These data are
consistent with our observation that increased p21 plays a role in the proliferative
advantage of oxidatively injured vSMC.  It has been proposed that the cdk inhibitor
p27 functions to inhibit cell proliferation during arterial repair, while p21 functions
as a cofactor induced in the latter phases of arterial remodeling to cause G1 arrest
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[91].   As well, oxidative stress has been implicated in modulation of cell cycle
regulation [63].
In our oxidative injury model of atherogenesis, we show that p27 levels were
not altered irrespective of the growth substrate, implying that p27 has little effect on
the proliferative advantage of allylamine cells compared with control cells.  The
increased expression of p21 observed in cycling allylamine cells seeded on a
permissive plastic substrate provides evidence that p21 may act as a permissive
element in vSMC cycle progression. Also, the normalization of p21 expression to
control levels in allylamine cells seeded on a collagen substrate establishes the
matrix dependency of p21 expression in randomly cycling oxidatively stressed cells.
In contrast to cycling cells, G0 synchronized allylamine cells express higher
levels of both p27 and p21 compared to control cells when grown on plastic.  Both
p27 and p21 allylamine/control ratios were increased in G0 synchronized cells when
grown on plastic compared with mitogen stimulation or growth on a collagen
substrate.  Cell cycle progression in both cell types resulted in decreased p27 levels
on both substrates, with a more pronounced effect when cells were grown on
collagen.  These findings are consistent with the growth inhibitory function of p27.
In contrast, following cell cycle progression, p21 protein expression increased in
control and allylamine cells when grown on both matrices.  We found no difference
in p21 or p27 expression following 9 hours of serum stimulation between cell types
irrespective of the growth matrix.  This indicates that differences exist at the basal
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level for cdk inhibitors in oxidatively injured vSMC compared to control cells, while
mitogen stimulation results in similar responses for p27 and p21 in both cell types.
Mitogenic stimulation for both cell types on plastic or collagen results in
decreased p27 expression and increased p21 expression.  p27 levels are similar in
both cell types during mitogen stimulation, and on both substrates, confirming that
this cdk inhibitor is not involved in the proliferative advantage of oxidatively
stressed vSMC. However, p21 expression shows less induction when cells are grown
on a non-permissive substrate compared with growth on plastic providing further
evidence of p21 as a positive regulator of growth in vSMC.  The growth inhibitory
effect of collagen in allylamine cells may occur post-9 hours of mitotic stimulation
and can be explained through the differential effects of growth factors on phenotypic
properties of vSMC [92].  For example, PDGF can initiate DNA synthesis, yet alone,
does not provide adequate signals for completion of DNA synthesis and cell cycle
progression.  Other growth factors, such as EGF, are required for cell proliferation,
consistent with previous studies from this laboratory showing that EGF synergizes
with the oxidative injury phenotype [76].
4.2. ERK1/2 Activation Profiles in Allylamine and Control Cells
The role of ERK1/2 in mediating extracellular matrix modulation of growth
properties in oxidatively stressed vSMC was also investigated in these studies.  MAP
kinases are intricately involved in modulation of growth, proliferation and
differentiation by growth factors and integrins [15,22,26,35].  Thus, MAP kinases
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may serve as points of integration for multiple signaling pathways, including those
involved in matrix-regulated cell cycle activity and proliferation. In our model of
oxidant induced vSMC injury, alterations of the extracellular matrix protein, OPN,
play a key role in modulation of vSMC phenotype [75,78].  It has been reported that
injury-induced OPN gene expression is dependent on activation of ERKs further
implicating the coordinated effort of integrin- and growth factor-mediated signaling
in modulation of vSMC phenotype [93].  It also has been reported that reactive
oxygen species, such as H2O2 and O2•−, differentially activate ERKs in vSMC [94]
implying that the phenotypic modulation of vSMC through metabolic conversion of
allylamine to reactive oxygen species may be dependent on ERK modulation.  Not
only is activation of ERKs crucial for cell growth, proliferation and differentiation, it
is clear that the temporal activation profile of ERKs is also  important in the cellular
response [95,96]. The typical activation profile of ERK is biphasic: a rapid phase
appearing within 15 minutes, followed by a sustained late phase of greater than 4
hours [96]. The sustained phase of ERK activation is an essential component for
growth factor-induced cell cycle progression.  When ERK activation is transient, the
immediate early gene product, c-Fos, does not accumulate.  However, sustained ERK
activity ultimately allows phosphorylation of accumulated c-Fos.  These temporal
differences in protein alteration patterns provide a means through which cells
interpret differences in ERK activation profiles [95]. Integrin-induced cell cycle
progression is also an important determinant for ERK activation kinetics.  Roovers
and colleagues show that α5β1 integrin sustains ERK1/2 activity resulting in
64
expression of cyclin D1 [41].  Loss of adhesion prevents cyclin D1 elevations thus
progression through G1 is blocked.
With this in mind, we evaluated the involvement of integrin/extracellular
matrix signaling in modulation of ERK activation kinetics in our model of
oxidatively injured vSMC.  Our results show that activation of ERK1/2 is of greater
magnitude and duration in allylamine cells compared to controls when seeded on
both plastic and collagen substrates.  Additionally, the kinetics of ERK1/2 activation
are remarkably different between cell types and growth substrate.  Growth on plastic
shows a much greater early peak in ERK1/2 activation in allylamine cells compared
to controls, while the sustained activity occurs, but not to the extent of the peak
activity.  In contrast, growth on collagen reveals a much lower early peak activity in
allylamine cells compared to controls yet the sustained activity is dramatically
enhanced over that seen in control cells.  Others have shown that MAP kinase
activation occurs through matrix/integrin signaling in adherent cells [32].   Morino et
al. (25) showed that fibroblast adherence to fibronectin, a ligand for the β1 integrin
subunit, as well as β1 crosslinking resulted in activation of MAP kinases.  ERK
activity plays an integral part in cell cycle regulation, specifically the passage from
G1 to S phase of the cell cycle [38,96].  Assoian et al. [39,44] have suggested that
matrix:integrin binding with fibronectin or vitronectin in vSMC leads to sustained
ERK activity.  This activity leads to translocation of the active enzyme to the nucleus
where it is required for synthesis of cyclin D1 and progression of the cell through the
cell cycle. Thus, interactions of integrins, MAP kinase and cell cycle control proteins
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may mediate dysregulated growth and differentiation of allylamine cells leading to
induction of highly proliferative phenotypes.  The early peak in ERK activation is
likely a combined effect of growth and integrin/extracellular matrix signaling leading
to ERK activation.  These data are suggestive that ERK activation is an important
contributing component of proliferative advantage and phenotypic alterations of
oxidatively injured vSMC and that the collagen modulation of the proliferative
advantage may be manifested through alteration of the activation profile of ERKs.
As seen for p21, peak ERK activation in vSMC was influenced by the
extracellular matrix, thus implicating interactions between ERK signaling and p21 in
the regulation of proliferation of vSMC.  Altered integrin/matrix regulation of ERK
and further downstream signaling events may contribute to induction of proliferative
phenotypes following oxidative injury by allylamine.  This interpretation is
consistent with the results of studies showing that basal levels of cyclin D1 are
increased in allylamine cells compared to control cells when cells are grown on
plastic, but not collagen (Jones et al., unpublished).  As cyclin D1 is an important
cell cycle regulatory protein involved in transition from G1 to S phase of the cell
cycle, alterations in cell cycle regulatory proteins through ERK1/2 activation may be
an important component of the proliferative dysregulation seen in oxidatively
stressed vSMC.
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4.3. ERK1/2 Contribution to p27 and p21 Expression in Allylamine and Control
Cells
To evaluate the contribution of ERKs in modulation of p27 and p21
expression, we utilized the MEK1/2 inhibitor, U0126, to suppress ERK activity.
Following inhibition of ERK activity, differential expression of p21, but not p27,
was observed between allylamine and control cells.  As cell cycle progression is
blocked through MEK 1/2 inhibition, increases in p27 levels are expected.  In this
model, no differences were observed in induction of p27 between the two cell types
grown on either substrate.  Thus, the alterations in p27 expression in oxidatively
injured cells are not dependent on ERK activation.  On the other hand, decreases in
p21 expression following MEK 1/2 inhibition were both cell and matrix dependent
with allylamine cells and the restrictive substrate, collagen, showing the most
depressed p21 levels.   It can be deduced, therefore, that ERK activation and p21
induction are related and contribute to the matrix dependent, proliferative advantage
observed in oxidatively injured vSMC.
4.4. Antioxidant Effects on p27 and p21 Expression in Allylamine and Control
Cells
Among the complex interactions of p21 with a myriad of proteins are
interactions with transcription factors C/EBP and NF-κB [87].  These factors have
been implicated in oxidative stress signaling in vSMC [61].  To further evaluate the
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effect of chronic oxidative injury on vSMC, we examined the influence of the NF-
κB inhibitor PDTC in this cell system.  PDTC can have a variety of effects on
cultured cells including pro-oxidant and antioxidant effects, immunomodulatory
actions, anti-apoptotic and apoptotic activity, as well as regulation of the activity of
redox-sensitive transcription factors, such as AP-1 and NF-κB [97-100].  These
effects appear to be concentration dependent as, for example, low PDTC
concentrations increase AP-1 binding activity while higher PDTC concentrations
inhibit NF-κB activity [100].  In our cell system of chronic oxidatively injured
vSMC, 100 nM PDTC pretreatment had a greater effect on p27 and p21 levels in G0
synchronized control cells grown on plastic than in any other treatment group.
Additionally, following mitogen stimulation, p27 was further suppressed by the
addition of PDTC, while PDTC had no effect on p21 levels when cells were grown
on plastic.  Compared with p27, a greater difference in p21 allylamine/control ratio
at 0 hour versus 9 hour PDTC treatment on collagen versus plastic was also
observed. Thus, high PDTC concentration suppresses the collagen/mitogen induction
of p21 in allylamine cells but not the plastic/mitogen response; whereas, p27 shows
enhanced suppression in allylamine cells compared to control cells on both
substrates. Following administration of lower concentrations of PDTC (25 nM) less
effect was observed.  For p27, a significant decrease in the allylamine/control ratio
was observed (p<0.05) when cells were grown on collagen in the presence of PDTC
and mitogen stimulation compared with all other treatment groups except PDTC pre-
treatment on both plastic and collagen.  No other significant differences were
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observed for p27.  p21 showed no significant differences between treatment groups
following 25nM PDTC administration.  However, a decreasing trend in the
allylamine/control ratios following mitogen stimulation was observed in the presence
and absence of 25 nM PDTC.  Influence of PDTC on this cell system thus appears to
be dose dependent.  Our results provide evidence that differential p21 expression in
oxidatively injured vSMC can be influenced by PDTC and the growth substrate.
4.5. Implications of Current Research
One of the key features in the pathogenesis of atherosclerosis and restenosis
is phenotypic alteration of vSMC from contractile to synthetic phenotypes, including
increased proliferative capacity.  Recently, the feasibility of targeting cell cycle
specific proteins as a therapeutic option to minimize or prevent this alteration has
gained credence.  Several of the methods which target cell cycle regulatory proteins
in vSMC that are currently under evaluation include: cell cycle modulating drug
therapy, oligodeoxynucleotide therapy (antisense and decoy strategies), adenoviral
mediated gene therapy, and liposomal-mediated gene therapy [88].  For example, the
drug tranilast interferes with p21-dependent vSMC hyperplasia in mice [101], while
short term therapy with pravastatin increases p27 expression resulting in inhibition of
vSMC growth and induction of apoptosis [102].  The success of pharmacological and
genetic approaches to vasculoproliferative therapy depends on the ability of the drug
to reach affected areas. There are many routes through which antiproliferative agents
may be administered (outlined by Sriram and Patterson) [89].  One of the most
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promising methods is through the use of drug-coated stents [103-106].  These
therapies appear promising in the prevention of re-stenosis following angioplasty or
in restarting proliferation in ischemia-damaged cardiac myocytes.  Our results offer
further evidence that, in the future, pharmacological or genetic manipulation of p21
may be an alternative or existing therapy for atherosclerosis induced by oxidative
injury.
4.6. Future Directions
The data presented in this dissertation suggest that integrin/extracellular
matrix signaling plays a crucial role in the development of the proliferative
phenotype of oxidatively injured vSMC.  Through alteration of ERK1 activation and
downstream cdk inhibitors, p27 and p21, oxidatively injured vSMC show
upregulation of cell cycle progression that is ablated on a collagen matrix.  Several
issues remain to be addressed to fully define the molecular mechanism regulating the
proliferative advantage seen in chronically oxidatively injured vSMC.  Screening of
a variety of cell cycle regulatory proteins, including cyclin D1, and cyclin E was
attempted.  However, difficulties arose in both variability of the cell cultures and
purchased antibodies.  It would be prudent, therefore, to further evaluate these
proteins and others, including the retinoblastoma protein, both through western
analysis and mRNA expression.  This would provide further insight into alterations
of cell cycle progression in oxidatively injured vSMC.
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One of the main issues that arose in performing the experiments within this
dissertation was the behavior of the allylamine and control cells.  Culture of vSMC
alters their phenotype from contractile to synthetic.  In our experiments, we are
investigating the mechanisms that modulate phenotype following oxidative injury in
vSMC.  In spite of cell culture conditions, allylamine cells maintained a proliferative
advantage over control counterparts following serial propagation [69].  However,
passage levels 20-25 were utilized in these experiments.  The underlying effects of
such high passage numbers in defining the mechanisms altering vSMC phenotype
are unknown.  Thus, further studies evaluating alterations in cdk inhibitor expression
in alternative oxidative injury models needs to be addressed.
By utilizing naïve vSMC, the effect of acute administration of oxidants such
as allylamine and its reactive oxygen species metabolites, acrolein and H2O2, may be
evaluated.  This would provide a means to study acute oxidative alteration of cell
cycle control and ERK activity.  In the cellular model used for these studies,
allylamine cells have been genetically altered by chronic administration of
allylamine.  Evaluation of matrix-dependent alterations of ERKs and cdk inhibitors
in an acute oxidative injury model may provide additional support for the
integrin/extracellular matrix- and growth factor- induced modulation of ERK
activation and cdk inhibitor expression in oxidatively injured vSMC.  Supplementary
studies involving transfection of p21 sense and antisense oligonucleotides into naïve
vSMC would offer further evidence of the importance of p21 regulation in the
matrix-dependent proliferative phenotype.  Matrix protein secretion has been altered
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through transfection of antisense p21 oligonucleotides [107].  Oligonucleotide
transfection studies can be performed to target the cdk inhibitor, p21, thereby
evaluating its requirement in cell cycle progression following perturbations of
integrin/extracellular matrix- and growth factor- dependent signaling cascades. This
provides an alternative protocol for evaluation of integrin/extracellular matrix
signaling and its effects on vSMC proliferation through modulation of cell cycle
regulatory proteins.
Finally, integral to the results presented in this dissertation, further
experiments addressing cellular localization of activated ERKs, p27, and p21 will
clarify mechanisms through which these proteins interfere with cell cycle
progression in oxidatively injured vSMC.  It is not only the expression levels of cell
cycle regulatory proteins that are important for modulatory activity, but post-
translational events such as the subcellular localization of proteins are relevant to
their functions [108-110]. Given that allylamine injured vSMC display an altered
kinetic profile of ERK activity, the events leading up to the proliferative advantage
acquired by allylamine cells may be the result of alterations not only in ERK
kinetics, but also in the cellular localization of activated ERKs.  The cellular location
of cdk inhibitors is an important component permitting the functional activities of
these proteins.  For example, contact inhibition in melanoma cells induced growth
arrest through sustained nuclear localization of p21 [108].  As well, cytoplasmic
relocalization of p27 in breast cancer cells inactivates the growth inhibitory
properties of this protein [109]. Additionally, in differentiating myeloid cells, the
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subcellular localization of p27 changes from nuclear to predominantly cytoplasmic
and finally to perinuclear localization at progressive stages of hematopoiesis [110].
Thus, matrix-dependent altered cellular location of ERK1/2 and p21 represents an
attractive hypothesis to explain the differences existing between proliferative rates of
control an allylamine cells.
4.7. Summary
In summary, evidence is presented here that chronic oxidative stress alters
expression of p27 and p21 in a matrix dependent manner.  Antioxidant
administration enhances the matrix dependent suppression of cdk inhibitors in vSMC
that have undergone repeated cycles of oxidative injury.  Differential ERK activation
profiles and differential expression of cdk inhibitors, p27 and p21, in allylamine cells
grown on plastic versus collagen indicate discrete alterations of integrin/ECM
signaling in oxidatively injured vSMC.  Thus, altered integrin/matrix regulation of
cdk inhibitors (p27 and p21), ERKs, and further downstream signaling events may
contribute to acquisition of proliferative phenotypes following oxidative injury by
allylamine.
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